Insider trading is if you have inside information. A buyer's intent to buy is not inside information. More like outside information. In fact it may not even be information unless the intent is disclosed or discovered. The extra volume for the past few days would be more in the range of 5% to 10% of outstanding shares (net of all the in/out shares by the robotraders). That is within the threshold of SEC reporting. So we may never know until much later. For allwe know it's those large hedge fund again buying in before a big announcement - be careful with that. The last time it happened was before the FDA approval. PPS went from $1.80 to $7.00 long before FDA approval. Popped to $11 at approval. After approval, the hedge funds unloaded and the price dropped significantly. I think I learned something from that and this time I will make more money than the hedge funds (relative to me of course).
Matt, with the new development around the 1st amendment promotion of drugs, you should hire a good attorney so that MNKD can promote Afreeza with those claims that are not on the label but are truthful and nonmisleading. The recent Amarin case decided that the FDA cannot prosecute on promotion of drugs that are based on truthful and non-misleading materials. Afreeza has a lot of materials in the clinical trials that were not permitted to be on the label. For example, "weight neutral" is supported by the clinical trials. "Ultra Fast" is supported by the clinical trials. These will make a difference in the marketing. Hire a good attorney to guide you through the new developments in regulatory enforcement. Or alternatively, if you are selecting a partner, make sure that the partner has the appetite and ability to be aggressive in its promotion of Afrezza beyond the label restrictions.
If this ruling came out two years ago OPC's class action would have been dismissed too.
March 4 — France-based Sanofi Pharmaceuticals Inc. can't be held liable for making false and misleading statements about a multiple sclerosis drug while it was under review by the Food and Drug Administration, an appeals court affirmed (Tongue v. Sanofi, 2016 BL 66168, 2d Cir., No. 15-88-cv, 3/4/16).
A little more than a year ago, the U.S. District Court for the Southern District of New York dismissed the plaintiffs' two related complaints, saying the challenged statements either were opinion statements of opinion or not materially misleading. It also said the plaintiffs didn't adequately allege scienter (the requisite mental state needed to commit fraud).
jmc is a fake. He is a physician asking a serious question from investors why one drug is better than another drug. Go figure.
jimcham, if you are truly physician you would know that even Lantus failed on its first year of commercialization. So to answer your question, we don't need any other products from the TS technology for this to skyrocket. We just need the proper marketing to be executed for Afrezza.
See for yourself:
"(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No
The big investors are months ahead of retail investors. They know this is going to pop again. The only question now for retail investors will this next pop hold. How far do we hold or learn from our prior mistakes? For me, I will look and see at what the deal that is announced. I expect:
1. Licensing deal for international sales of Afreeza with significant upfront payment;
2. U.S. market will be non-exclusive deal allowing MNKD to sell alongside another licensed partner; upfront payment + cost
By: Matt Pfeffer (LA Times Comment Section)
Al was a truly great man who will be missed by all, but by me in particular. I am honored to have been able to call him my friend, as well as my mentor and my inspiration. His untimely passing only makes me more determined to honor his legacy by working tirelessly to make MannKind Corporation, and its revolutionary first product, Afrezza, the tremendous success he always believed it would be. Al helped so many, not only with his amazing and revolutionary advances in health care, but particularly through his many philanthropic efforts. There will never be another like him. He will never be forgotten
audiomr, believe it or not, some people are paid to do just that; insult, lie, mislead, confuse, intimidate, misinform.
rocwillow, message boards of highly shorted stocks are all like this. The shorts thrive on misinformation and chaos. It is up to good people to see through this and prevail.
You call everyone a moron but you lost your shirt on MNKD long before most of us ever heard of MNKD. So what did the class action lawsuit settlement give you? A Lobotomy?
You've got the wrong person. I am not short. You may want to wait until your awake before you post.
OPC, and how do you know it is not the same shorts? Aren't you the guy that kept saying the shorts were covered by the warrants and calls? The warrants are gone and the short volume did not go down. The only thing that exceeds your foul mouth is your stupidity.
I mean't the shorts don't need to be right. They don't care if they are wrong. They just need to outlast the longs. But they've met their match with the MNKD cult. Sorry shorts, my MNKD shares are in my IRA. So I don't care if it takes another 5 years! Will you be around then?
The shorts theory is that they do not have to right. They just need to outlast the bagholder longs. Well, it looks like the've met their match. Kevinmink is still posting predictions while Colton is still paying 40% interest on their borrowed shares. The big difference is Colton doesn't care - it's not his money. He gets paid to bash.